Patents by Inventor Silke Gillessen

Silke Gillessen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10226476
    Abstract: The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: March 12, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: S. Brian Wilson, Glenn Dranoff, Silke Gillessen
  • Patent number: 10151755
    Abstract: The invention relates to biomarker assays based on protein/peptide biomarkers which show a pronounced differential behaviour between healthy and cancerous sample proteomes e.g. by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the protein biomarkers in serum, plasma or blood itself.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: December 11, 2018
    Assignees: ETH ZURICH, Kantonsspital St. Gallen
    Inventors: Wilhelm Krek, Igor Cima, Rudolf Aebersold, Ralph Schiess, Thomas Cerny, Silke Gillessen
  • Publication number: 20160274117
    Abstract: The invention relates to biomarker assays based on protein/peptide biomarkers which show a pronounced differential behaviour between healthy and cancerous sample proteomes e.g. by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the protein biomarkers in serum, plasma or blood itself.
    Type: Application
    Filed: June 1, 2016
    Publication date: September 22, 2016
    Applicants: ETH ZURICH, Kantonsspital St. Gallen
    Inventors: Wilhelm KREK, Igor CIMA, Rudolf AEBERSOLD, Ralph SCHIESS, Thomas CERNY, Silke GILLESSEN
  • Patent number: 9377463
    Abstract: The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behavior between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from health
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: June 28, 2016
    Assignees: ETH ZURICH, Kantonsspital St. Gallen
    Inventors: Wilhelm Krek, Igor Cima, Rudolf Aebersold, Ralph Schiess, Thomas Cerny, Silke Gillessen
  • Publication number: 20160074423
    Abstract: The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.
    Type: Application
    Filed: July 17, 2015
    Publication date: March 17, 2016
    Inventors: S. Brian Wilson, Glenn Dranoff, Silke Gillessen
  • Publication number: 20140322732
    Abstract: The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healt
    Type: Application
    Filed: June 23, 2014
    Publication date: October 30, 2014
    Applicants: Kantonsspital St. Gallen, ETH ZURICH
    Inventors: Wilhelm KREK, Igor CIMA, Rudolf AEBERSOLD, Ralph SCHIESS, Thomas CERNY, Silke GILLESSEN
  • Publication number: 20140286949
    Abstract: The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.
    Type: Application
    Filed: October 25, 2013
    Publication date: September 25, 2014
    Applicant: Dana-Farber Cancer Institute
    Inventors: S. Brian Wilson, Glenn Dranoff, Silke Gillessen
  • Publication number: 20110065605
    Abstract: The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healt
    Type: Application
    Filed: May 12, 2009
    Publication date: March 17, 2011
    Applicants: ETH ZURICH, KANTONSSPITAL ST. GALLEN
    Inventors: Wilhelm Krek, Igor Cima, Rudolf Aebersold, Ralph Schiess, Thomas Cerny, Silke Gillessen
  • Publication number: 20080260680
    Abstract: The present invention is directed to a method of inhibiting CDld activation by administering a composition containing a moiety that blocks CDld activation. Compositions of the invention are useful for the attenuation of CDld-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.
    Type: Application
    Filed: June 25, 2008
    Publication date: October 23, 2008
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: S. Brian Wilson, Glenn Dranoff, Silke Gillessen
  • Patent number: 7419958
    Abstract: The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: September 2, 2008
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: S. Brian Wilson, Glenn Dranoff, Silke Gillessen
  • Publication number: 20020165170
    Abstract: The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.
    Type: Application
    Filed: March 26, 2002
    Publication date: November 7, 2002
    Inventors: S. Brian Wilson, Glenn Dranoff, Silke Gillessen